<?xml version="1.0" encoding="UTF-8"?>
<ack>
 <title>Acknowledgments</title>
 <p>The EBO-Z GP trimeric protein was produced and donated by Dr. Jing Jin and Professor Simon Draper at the Jenner Institute (Oxford, UK).</p>
 <p>The Oxford clinical trial was supported by funding from an Enhancement Award to a Wellcome Trust Strategic Award (to A.V.S. Hill as principal investigator) cofunded by the UK Medical Research Council, the UK Department for International Development, and the European and Developing Countries Clinical Trials Parnership, with additional funding from the National Institute for Health Research Oxford Biomedical Research Centre.. GlaxoSmithKline Biologicals SA supplied the ChAd3–EBO-Z vaccine and had the opportunity to review this manuscript. The MVA–EBO-Z vaccine was biomanufactured for these trials by Emergent Biosolutions under a contract from Oxford University with funding from the same Enhancement Award. The Senegalese trial was largely funded by a European Commission Horizon 2020 program award, EbolaVac (
  <ext-link ext-link-type="uri" xlink:href="http://www.ebolavac.eu" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.ebolavac.eu</ext-link>), grant agreement no. 666085.
 </p>
 <p>Author contributions: G. Bowyer conceptualized the study. K.J. Ewer, N. Venkatraman, T. Dieye, S. Mboup, and A.V.S. Hill designed the clinical studies. N. Venkatraman and P. Birahim Ndiaye conducted clinical work. G. Bowyer, H. Sharpe, C. Mair, D. Wade, and N. Brenner conducted the investigations. G. Bowyer wrote the original draft of the manuscript. N. Brenner, A. Mentzer, and T. Waterboer designed the multiplex serology assay. All authors reviewed and edited the manuscript. K.J. Ewer, S. Mboup, T. Lambe, T. Waterboer, and A.V.S. Hill supervised the study.</p>
</ack>
